Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.
Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.
AstraZeneca announced the end of the investigation Tuesday.
Amgen now hopes a separate study will be enough to support the drug's advancement to a second-line therapy, but the lackluster results may impinge on its EU filing schedule.
Blood-cancer drug Kyprolis outperformed standard treatment in a late-stage trial testing the drug in patients with multiple myeloma, said Amgen.
The company is calling the move a withdrawal, as opposed to a recall.
A study indicates they may do little to reduce the risk of stroke or heart attack.
HPV testing provides an edge over Pap screenings when it comes to detecting cervical cancer risk.
An international AIDS conference this weekend kicked off a new battle in the war against hepatitis C: demonstrating high cure rates in those who are co-infected.
Novartis and the nonprofit Banner Alzheimer's Institutes are testing a theory that treating healthy patients could prevent or delay Alzheimer's disease.
Cyramza patients had more favorable overall survival rates than placebo patients, but the differences were not statistically significant.
The Wall Street Journal notes that a new study on testosterone therapy has some weaknesses, including its sole focus on men who received injections—leaving out pills, patches and gels.
Editorial says risk is small, researchers say it could be clinically relevant.
The American College of Physicians says most women do not need an annual pelvic exam. The American College of Obstetrics and Gynecologists disagrees.
The regulator wants men to be part of breast cancer clinical trials.
An FDA advisory panel voted 11-2 against an accelerated approval for AstraZeneca's experimental PARP inihibitor. The panel recommends getting more data before giving the drug the all-clear.
The firm ended the Phase III trial for its ballyhooed immunotherapy, which showed superior survival compared to chemo in advanced melanoma.
An experimental Gelesis weight-loss drug seeks the middle ground between surgery and appetite suppressants.
Phase III results showing improved lung function among cystic fibrosis patients using a combination of Kalydeco and lumacaftor means drugmaker Vertex is filing the two-part drug for FDA approval during the fourth quarter.
BI says there is no unmet need for faldaprevir.
GlaxoSmithKline dismissed a marketer over its approach to clinical trial recruiting.
Gene mutations lead researchers to rethink ways to protect the heart.
The drugmaker has told global regulators it failed to share 10,000 reported cases of side effects for a variety of its drugs.
Patients taking a high-dose form of Novo Nordisk diabetes drug Victoza saw an average weight loss of 5.9% of their body weight, data from a study show.
The FDA granted the label for Genentech's experimental metastatic urothelial bladder cancer treatment.
The potential of immunotherapy is great, but the news from the 2014 medical meeting shows that great may not be gargantuan in terms of treatment reach.
The CDC said Thursday that most of the 288 recent US measles cases were caused by un-vaccinated travelers who brought the virus home with them.
The regulator is allocating almost $38 million to improve data-guided decision-making.
The drugmaker is set to start patient testing.
The companies announced Tuesday that Arzerra, already indicated for leukemia, failed to outdo Roche's Rituxan in the lymphoma setting.
The Securities and Exchange Commission alleges that two doctors illegally exploited their clinical trial affiliation for financial gain.
Both companies revealed Phase-III data for idiopathic pulmonary fibrosis treatments. The progressive disease generally kills patients within three years of diagnosis.
Gelesis is pouring money into its obesity "smart pill," and Novo reports weighty success among subjects taking liraglutide.
The drugmaker announced Wednesday that researchers would be able to access clinical trial data.
GlaxoSmithKline announced Tuesday its Phase-III drug from the Human Genome Sciences acquisition failed to hit its primary endpoint.
Phase-III results for Eli Lilly basal insulin peglispro showed superior blood sugar reduction vs. Sanofi's Lantus in trials, but a number of safety issues could hurt its appeal.
The company announced Monday that researchers will be able to seek out clinical trial data going back to 1998.
FDA warned consumers against using aspirin for primary prevention, following its denial of Bayer's request to allow marketing of aspirin for that use.
According to an analysis of final data from one of the WHI's trials, each dollar received results in a net economic value of $140.
Merrimack Pharma said its candidate for pancreatic cancer increased overall survival, and that it plans to file applications in the US and EU this year.
Two drugmakers, Purdue Pharma and Teva, have abuse-deterrent hydrocodone medications either under FDA review or in late-stage testing.
Panel chair Randall Flick said QRxPharma "had not provided sufficient evidence to support a claim that Moxduo is safer than morphine or oxycodone."
The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.
Phase-II results indicate Merck's all-in-one HCV oral could put pressure on Gilead.
The FDA issued an official halt, five days after Halozyme stopped the Phase-II trial because of patient stroke information.
Researchers found a correlation between patients feeling involved and how well they stick—if they stick—to their medication regimens.
Phase-III results prompted the drugmaker to pursue a third-quarter filing.
Researchers find public service announcements and physician information don't change minds, but a California practice found one way it could.
Analysts say the Indianapolis, IN, drugmaker's Phase-I results show CDK 4/6 inhibitors will have a role in breast cancer treatment and that Pfizer's palbociclib will not clear the field.
Sunday's data readout has divided the Street between the enthusiastic and the disappointed. The key reason: progression-free survival gains were not as high as anticipated.
The drugmaker is ceasing a trial called MAGRIT after it was unable to identify patients who could benefit from MAGE-A3.
The drugmaker saw positive results in demonstrating LDL reductions in Japanese patient populations.
Detailed Phase-III results from several PCSK9 candidates confirm the clinical ability of the newest class of cholesterol-lowering treatments.
The drugmaker said successful results prompted an independent Data Monitoring Committee to recommend stopping the trial. The news follows an uneven week of pipeline drug news.
The FDA has approved a 24-hour version of Pfizer's heartburn medication.
A rival's late-stage trial results suggest the pain med may have a short market life. The key: an FDA division head's documented willingness to overturn the approval should another pain option surface.
Pfizer hit its endpoints for preventing pneumonia among the elderly, but the data may not be robust enough to spur vaccination.
Bayer and Amgen's Onyx subsidiary announce an oncology drug failed a Phase-III trial goal among liver cancer patients.
Sanofi and the firm with which it's co-developing alirocumab disclosed that regulators want some patients to be assessed for neurocognitive side effects.
Data presented at a conference yesterday suggest AbbVie's all-oral regimen may be more effective than Gilead's at curing the virus in certain patients, but will it confer an edge?
A study says that more opioid abusers get their medications via prescription than they do second-hand.
Sanofi top-lined positive clinical data today from its investigational basal insulin, as it seeks to defend its position in this fast-growing segment.
The drugmaker says interim trial data meets FDA review requirements and is hoping for June 2014 approval.
New results from its Phase II safety trial show the LDL-cholesterol lowerer was not associated with a major increase in adverse events vs. standard of care.
An investigational cardiovascular heart drug failed to reduce the risk of heart attack or stroke, a miss which some on Wall Street say raises questions about the drugmaker's ability to deliver in late-stage trials.
Safety reviewers' reservations about the MS drug's risk profile, unveiled in briefing documents ahead of an ad-com meeting, suggest it won't be smooth sailing for the drug in the US.
The drugmaker blasted the price-control agency for being shortsighted and underestimating the industry's role in health and savings.
The drug company is ceasing US distribution and marketing the leukemia drug after the FDA said it was worried about blood clots among clinical trial patients.
The FDA told the drugmaker in a letter before the December PDUFA date that evidence does not support an expanded indication.
The AAP says greater access and education are critical in curbing STIs.
The hep. C drug is safe and effective when used in combination with other therapies, according to information posted by FDA reviewers.
Word came of Breakthrough Designation for an HCV hopeful, a day after a hiccup in a heart drug trial.
A report says oncologists may be using GSK's Tafinlar and Mekinist together in a non-FDA approved combination therapy.
Adding Epzicom to Tivicay in a once-daily cocktail could further boost GSK's HIV franchise, and possibly chip away at Atripla's dominance.
On Monday Regeneron reported more positive Ph. III data for its wet AMD/macular edema drug Eylea (aflibercept).
Lantus-like rivals can expect a wary reception from endocrinologists, even if these biosimilars reach market, researchers predict.
The agency says the copycat antidepressant failed to meet bioequivalency requirements.
In schizophrenia, non-compliance can be disastrous. Do depot drugs really make a difference for patients?
An analyst notes that early Phase III results in a psoriasis clinical trial could change the drug's efficacy profile. It could also fill out the financial potential of a standalone innovative unit, should Pfizer divide.
The drug maker says a patient's physician did not link the MS drug to her death.
The drug maker says it is accelerating development of new drugs and focusing on expanding indications of current ones.
Recent studies underscore a need for greater engagement in multicultural communities.
Monday's announcement builds on a stream of recent R&D relationships.
A public information request details closed-door meetings in which industry players paid to sit with government employees and talk pain-medication efforts.
Researches say cognitive enhancers, a group which includes drugs like Aricept and Exelon, fail to slow decline in patients with Alzheimer's over the long term.
Eli Lilly is the first Big Pharma to team up with the agency in its rare-disease pre-clinical development program.
GlaxoSmithKline heats up the CLL category with its second breakthrough designation therapy of the year, topped off by priority review for a melanoma combo treatment.
Bristol-Myers Squibb said Thursday that the drug failed to hit its primary goal in a prostate cancer trial, but some analysts say the data is not the last word on its potential in this tumor type.
The advisory panel endorsed the treatment with an 11-2 vote.
The changes, which include tightening prescribing criteria of extended-release and long-acting opioids and a boxed warning for pregnancy, are part of an effort to curb abuse. Some said the FDA's effort is too limited
The experimental LAMA/LABA combination could shake up the category.
Price, market potential and emotional pull make this subcategory of orphan diseases one to watch, an analyst writes. Hint: it's not oncology.
For women suffering from breast cancer, online tools appeared to be helpful in battling depression, a randomized trial showed.
Researchers say a two-year study shows the DPP-IV drug is not linked to a higher cardiovascular risk.
Squeezed in the wet AMD space, Roche could get some eye-care breathing room if it can snag first-to-market status in the dry AMD category. Early results bode well.
Two of the most difficult-to-treat hepatitis C patient groups saw high cure rates in an NIH-led study, results released Tuesday show.
Sales may be rising, but a new study finds current psoriasis therapies leave room for improvement. Over half of patients said they want better options.
Phase II studies found recreational abusers were not significantly bothered by the mechanism meant to make a "deterrent" version unpleasant to snort.
Amgen's newest oncology asset could reach great heights, if the firm can capitalize on its existing commercial and R&D capabilities.
Phase III results of its Crohn's and ulcerative colitis medication show positive patient response in a category among patients who have exhausted other options.